Workforce-related |
|
|
Reduced clinical research workforce
|
Contract COVID-19
Reduced staff (furloughs, job loss)
Work from home mandates
|
Delay in patient recruitment
Delays data collection and submission
Potential compromise in data quality
|
Reduced laboratory research workforce
|
Contract COVID-19
Reduced staff (furloughs, job loss)
Work from home mandates
Exclusion of trainees due to social distancing
|
Little to no laboratory research being performed beyond “essential”
Delays in publications, grant submissions, report deadlines due to
incomplete data
Delayed or compromised training of future workforce
|
Reduced capacity of institutional review board (IRB)
|
Reduced staff (furloughs, job loss)
Work from home mandates
More protocol amendments
Influx of COVID-19-related protocols
|
Deferred or prolonged new protocol review
Prolonged review of protocol amendments
|
On-site monitoring suspended
|
Sponsor (furloughs, job loss, work from home mandates)
|
Reduced interaction with sponsor
Less sponsor oversight, increased data errors
|
Consent process by phone |
Phone consent |
Compromised patient
understanding especially low socio-economic status
patients |
Research |
|
|
Observational research (natural history) |
Deemed nonessential |
Gaps in
registry patient data |
Biorepository databases |
Deemed nonessential |
Less patient
biospecimens |
Phase I and II trials |
Suspended |
Less treatment options for patients
with relapsed, refractory disease |
Reduced clinical revenue from hospital |
Decreased patient volumes |
Furloughed or permanent loss of clinical research
workforce |
Funding |
|
|
Institutional |
Reduced patient care volumes, budget |
Slower discovery
and delayed impact on patients |
Government |
Limited or reallocated resources |
Slower discovery and
delayed impact on patients |
Philanthropic |
Reduced funding due to lower donations |
Slower
discovery and delayed impact on patients |